Literature DB >> 2922705

Fibrinolytic activity of normal human blood monocytes.

E Grau1, L A Moroz.   

Abstract

Neutrophils (PMN) are important in the cellular phase of blood fibrino lytic activity (FA). The contribution of monocytes (MC), which have FA, is unclear. To determine the relative roles of these cells to activity in normal blood, we examined, by solid phase radiofibrin assay, FA of normal blood and plasma, and of purified PMN and MC, with and without plasminogen (PLG), mini-plasminogen (mPLG), the other major elastase fragment of PLG, or autologous plasma. PMN alone (0.5 x 10(6)/ml) had striking activity (292 +/- 25 SEM ng fibrin lysed/h; n = 10 normal subjects) while MC alone (0.5 x 10(6)/ml) had mean FA of 32 +/- 4 ng/h, which could be accounted for by contaminating PMN (36 +/- 8 ng/h). Thus, in a 1 h assay (when cellular FA accounts for 70-80% of FA in whole blood), normal numbers of MC (0.5 x 10(6)/ml) had no detectable FA when assayed with PLG or normal plasma. With longer assay times (2-6 h), PLG-dependent (plasminogen activator, PA) activity was demonstrated with mixtures of MC and PLG or plasma. This PA activity was released into the medium and required prior contact of MC and an intact, soluble PLG molecule for PA activity to be detected in medium (suggesting a PLG-MC triggering mechanism), since activity was reduced or absent when MC were exposed to mPLG, the other major elastase fragment of PLG, or solid phase PLG. Exposure of MC to solid phase fibrin did not result in PA release. MC PA activity was little affected by cycloheximide pretreatment, indicating preformed rather than newly synthesized PA. By SDS-PAGE and fibrin zymography, MC extracts revealed a single PA band with features of pro-urokinase (single chain urinary-type PA): Mr 55,000, inhibition by antiurokinase antibody (but not by anti-tPA), and resistance to inhibition by DFP. By ELISA assay, approximate normal monocyte content of this PA (as Mr 55,000 urokinase) was 0.03 fg (3.3 x 10(8) molecules) per cell.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2922705     DOI: 10.1016/0049-3848(89)90375-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Maspin increases extracellular plasminogen activator activity associated with corneal fibroblasts and myofibroblasts.

Authors:  Debra J Warejcka; Malathi Narayan; Sally S Twining
Journal:  Exp Eye Res       Date:  2011-07-27       Impact factor: 3.467

2.  Induction of the plasminogen activator system accompanies peripheral nerve regeneration after sciatic nerve crush.

Authors:  L B Siconolfi; N W Seeds
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

3.  Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

Authors:  R Pannell; S Li; V Gurewich
Journal:  J Thromb Thrombolysis       Date:  2017-08       Impact factor: 2.300

4.  Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia.

Authors:  R A Fava; N J Olsen; A E Postlethwaite; K N Broadley; J M Davidson; L B Nanney; C Lucas; A S Townes
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

5.  The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes.

Authors:  Catherine P M Hayward; Minggao Liang; Subia Tasneem; Asim Soomro; John S Waye; Andrew D Paterson; Georges E Rivard; Michael D Wilson
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

Review 6.  Fibrinolysis and Inflammation in Venous Thrombus Resolution.

Authors:  Subhradip Mukhopadhyay; Tierra A Johnson; Nadire Duru; Marguerite S Buzza; Nisha R Pawar; Rajabrata Sarkar; Toni M Antalis
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.